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Abstract
Background: It is important to be able to predict cancer incidence and mortality rates for planning and managing the risk factors.
Objectives: The present study investigated the changes in the incidence and mortality rates of five most common cancers in Iran.
Methods: The cancer incidence and mortality data were obtained from the national cancer and mortality registries. Five most common cancers in
both men and women were selected. Changes in the incidence and mortality rates of the selected cancers in both sexes were estimated by age group,
annual percent change (APC), and average APC (AAPC) and then graphically displayed.
Results: The most common cancers (except skin cancer) were breast, colorectal, stomach, esophageal, and thyroid cancers in women and stomach,
prostate, bladder, colorectal, and esophageal cancers in men, respectively. The AAPCs of all cancer incidence rates had increased by 11.9% in men
and 11.6% in women from 2002 to 2010. Also, the mortality rates had enhanced by 0.4% and 0.1% per year in men and women from 2006 to 2011,
respectively. The greatest APC was reported in prostate cancer. The rate had increased by 41.9% from 2002 to 2004, by 13.4% from 2004 to 2008, and
slowly augmented by 3.9% from 2008 to 2010. In women, the greatest APC was observed in colorectal cancer; the rate had enhanced by 13.4% per year
from 2002 to 2010. The greatest increase for age-standardized mortality and incidence in 2011 was attributed to gastric cancer (12.5% and 17.1% per
100,000 men, respectively). In women, the highest age-standardized mortality rate was related to gastric cancer at 6.9% per 100,000 women. The
incidence and mortality patterns of colorectal and esophageal cancers in men and women were similar, although they were slightly higher in men
than women.
Conclusions: Overall, cancer incidence rates had increased in both sexes. Many factors were responsible, such as changes in lifestyle, environmental
factors, increased life expectancy, improvements in the registration systems, and declining mortality rates due to early detection and treatment. The
results of this study provided useful information for the prediction of changes in the incidence and mortality of cancer and subsequent design of
cancer control programs in Iran.
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1. Background
Cancer is a major cause of mortality worldwide. As
the population advances in age, the increase in risk fac-
tors raises the burden of cancer (1). Globocan estimated
that 14.1 million new cases and 8.2 million deaths occurred
globally in 2012, with the burden shifting towards develop-
ing countries (2). Nevertheless, in some developed coun-
tries, a noticeable decline has occurred. For instance, in the
United States, cancer mortality rate decreased from 215.1
per 100,000 persons in 1991 to 168.7 in 2011 (almost a 22%
decline) (3).
The American cancer society predicts that the most
common cancers in the United States include prostate,
lung and bronchus, and colorectal cancers in males and
breast, lung and bronchus, and colorectal cancers in fe-
males. The highest mortality rates are attributed to lung
and bronchus, prostate, and colorectal cancers in males
and lung and bronchus, breast, and colorectal cancers in
females (3). In Europe, the most prevalent types of cancer
in 2012 were breast, colorectal, prostate, and lung cancers,
while the most common causes of cancer-related death
were lung, colorectal, breast, and stomach cancer (4).
Cancer is the third leading cause of mortality in Iran
(5). A survey in 2010 found that the five most prevalent
cancers in both genders except skin cancer were stomach,
esophageal, breast, prostate, and colon cancers; also, there
were slight differences between genders (6). Overall, as
more risk factors develop and spread, the incidence and
mortality of cancer is expected to increase (7).
Studies have shown an increasing trend in the global
incidence and mortality of cancer (8), especially in devel-
oping countries (9). However, some studies have reported
a decreasing trend in cancer mortality (10). It is important
to be able to predict the incidence and mortality of can-
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cer in order to be able to plan and manage the risk factors.
Trend analysis is useful for predicting such changes (11).
Although the incidence and mortality rates of cancer
could be analyzed, using Poisson’s regression and nega-
tive binomial regression models (12), joinpoint regression
analysis allows visualization of these changes and finds
the best fit for the incidence and mortality trends (13).
Moreover, by using the joinpoint regression analysis, the
authors can investigate the changes over distinct periods
of time (14) and can measure the average annual percent
change (AAPC) instead of the annual percent change (APC)
(13).
APC constantly assumes the rate of changes, which
could be a main limitation, as changes in some subgroups
(sex, age, and race subgroups) may vary. This limitation
could be more important, when the study period is length-
ened. However, through applying AAPC, we can consider
trend transition (13, 15).
2. Objectives
The present study investigated the changes in the inci-
dence and mortality rates of five most prevalent cancers in
Iranian males and females.
3. Methods
3.1. Data Sources
In this cross-sectional study, we analyzed the available
national cancer data. Information concerning the inci-
dence of cancer (2002 - 2010) was obtained from the na-
tional cancer registry, and morality-related data (2006 -
2011) were retrieved from the center for health network
management of the ministry of health and medical educa-
tion. In the national registration system of Iran, the center
for disease control collects and analyzes cancer informa-
tion. This center receives data about cancer patients from
health centers in different cities and provinces. Due to the
time lag in collecting and recording the cancer data, the
latest available national data were used.
Classification and coding of cancer were based on the
international classification of diseases for oncology (ICD-
O) standards by the world health organization (12). In-
formation on all cancer-related deaths, recorded in all
provinces of Iran (except Tehran and Alborz), was col-
lected from medical universities and colleges by the cen-
ter for health network management and was classified and
coded, based on ICD-10. Only the data related to Iranian
patients in the defined period of time were examined, and
data collection was performed by the first author. The pop-
ulation figures from 2006 and 2011 censuses were used to
calculate the trends. For other years, population informa-
tion by the statistical center of Iran (SCI) was applied for
predictions, according to age and gender groups.
3.2. Statistical Analysis
In order to assimilate the data, all the codes were con-
verted to ICD-10. The five most common cancers in men
and women were then selected and compared. The sam-
ples were divided into 18 age groups of five years. The equal
variance choice was assumed, and the maximum number
of joinpoints was 2 points for cancer incidence and 1 point
for mortality. The network search method (grid search
method) was selected to determine the number of join-
points. A significance level of 0.05 was applied.
The age-standardized incidence rate was calculated, us-
ing the direct standardization method and standard world
population in 2000 per 100,000 people (WHO report).
The incidence and mortality rates, number of new can-
cer cases, and deaths per year were calculated for the esti-
mated population at risk in the same year.
To plot the graph, the easiest possible joinpoint model
for cancer was fitted, using the network search technique
(grid search method). Next, the minimum and maximum
joinpoints were determined and their statistical signifi-
cance was tested. For cancer incidence, 0 - 2 joinpoints and
for mortality, 0 - 1 joinpoint were used; the results were re-
ported, based on the maximum number of joinpoints.
APC, AAPC, and line slope were then estimated.
Changes in the incidence and mortality of selected
cancers for both genders and different age groups were
determined, and the APC was estimated at a 95% confi-
dence interval (CI). The latest version of joinpoint software
4.2.02 by the national cancer institute (Surveillance, epi-
demiology, and end results program, June 2015) was used
for the analysis.
4. Results
In 2002 - 2010, a total of 514,550 cases of cancer were
recorded, 55.8% of whom were men. Also, there were
175,199 cases of death due to cancer in 2006 - 2011 (66.6%
were men). Table 1 shows the incidence of five main can-
cers for each gender. The age-standardized incidence in
men and women increased over the study period (Fig-
ure 1). The AAPC based on the age-standardized incidence
rate for all cancers combined increased by 11.9% for men
and by 11.6% for women (Table 1). The AAPC of mortal-
ity based on the age-standardized rate increased by 0.4%
for men and by 0.1% for women (Table 2). Based on the
age-standardized mortality rate in 2011, death from gastric
cancer was ranked first (12.5), followed by prostate (6.3),
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esophageal (3.3), colorectal (3.2), and bladder (1.7) cancers
(Table 3).
The highest age-standardized incidence rates in men
were attributed to gastric (17.1) and prostate (13.8) cancers,
which was similar to the mortality rates and ranked the
highest. These cancers were followed by bladder (11.8), col-
orectal (11.3), and esophageal (5.6) cancers (Figure 2). In
women, the highest mortality was due to gastric cancer
(6.9), followed by breast (5.7), esophageal (2.4), colorectal
(2.2), and thyroid (0.3) cancers (Table 3).
The highest age-standardized incidence rate in women
was related to breast cancer (30.2), followed by colorectal
(10.3) and gastric (8.9) cancers; esophageal and thyroid can-
cers ranked below gastric cancer (Figure 3). The pattern
of the incidence and mortality of colorectal cancer in men
and women was similar and increasing, although it was
slightly higher in men than women (11.3 versus 10.3 for in-
cidence and 3.2 versus 2.2 for mortality, respectively; Fig-
ures 1 and 4). The patterns of the incidence and mortality
of esophageal cancer were similar in men and women, al-
though they were slightly higher in men than women (Fig-
ures 1 and 4).
4.1. APC Analysis
Tables 2 and 3 show the increase or decline in the inci-
dence and mortality rates, based on the changes in APC.
4.2. Increasing Incidence
The AAPC for the incidence of the selected cancers for
men and women increased during the study period, based
on the age-standardized incidence; this trend was signifi-
cant at P < 0.05. During 2002 - 2004, the APC in women
was 34.8% for gastric cancer, 27.4% for colorectal cancer,
and 37.1% for esophageal cancer. The rate for all cancers
increased by 27.3%, although it was not statistically signifi-
cant (Table 1).
4.3. Increasing Mortality
The age-standardized rate of mortality for colorectal
and prostate cancers increased in men, although the trend
was not statistically significant.
4.4. Decreasing Incidence
From 2008 to 2010 (trend 3), the incidence of all can-
cers (except thyroid cancer in women and prostate cancer
in men) was negative, and none of the APC values for cancer
incidence during this period were statistically significant.
4.5. Decreasing Mortality
Despite the rise in the age-standardized incidence of
esophageal and bladder cancers in men (Figures 1 and 2),
the AAPC for these cancers in men showed a decreasing
trend (4.9% and 3.8%, respectively), and the decline was
statistically significant. The decrease in age-standardized
mortality of esophageal (5.4%) and colorectal (1.2%) cancers
was statistically significant in women.
5. Discussion
All cancers showed an increasing trend for the age-
standardized incidence rates until 2008; these figures
were significant for women and insignificant for men. Af-
ter 2008, a decreasing trend was observed in both genders.
A roughly steady age-standardized mortality rate was ob-
served for all cancer sites. More precisely, there was a fairly
decreasing trend from 2006 to 2009 and a slight increas-
ing trend from 2009 to 2011, all of which were statistically
significant.
The present study is the first research in Iran using the
joinpoint regression model on a national scale to analyze
both the incidence and mortality of cancer in Iran. In this
regard, a previous study only included three provinces of
Iran, namely, Gilan, Golestan, and Mazandaran. The afore-
mentioned study in northern Iran indicated that the age-
standardized incidence rate increased significantly from
2004 to 2009, with estimated AAPC values of 10.3% for
Gilan, 8.5% for Mazandaran, and 5.2% for Golestan (9).
In 2008, the population-based cancer registry was estab-
lished in Iran by 17 universities and reported an average 16%
increase in cancer incidence (16).
The high incidence rates in 2008 could be to some
extent attributed to the population-based cancer registry.
Moreover, recently, efforts have been made to collect as
much data as possible from pathology centers; hence,
higher incidence rates should be expected. Age is consid-
ered as the most important risk factor for cancer incidence
(17). According to two latest censuses in Iran, the propor-
tion of people over the age of 60 years increased from 6.6%
in 1996 to 8.2% in 2011 (18). The aging population is another
probable reason for the increase in cancer incidence in re-
cent years.
The results showed an increasing trend for the age-
standardized incidence of esophageal cancer from 2002 to
2008; however, this became a decreasing trend from 2008
to 2010. The increasing trends in both genders could be
attributed to unknown risk factors, unhealthy dietary pat-
terns, drinking hot beverages, and low intake of fruits and
vegetables (19). Stomach cancer, e.g., esophageal cancer,
has a high incidence rate in Eastern Asia, while the rates
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Table 1. Trends in Age-Standardized Incidence Rates for All and Major Cancers in Iran Among Men and Women According to the Joinpoint Analysis in 2002 - 2010
AAPC in 2002 - 2010 Trend 1 Trend 2 Trend 3
AAPCa 95% Confidence Interval P Value Years APCb Years APC Years APC
Lower Upper
Males
All sites 11.9 9.5 14.4 0 2002 - 2004 35.1 2004 - 2008 9.5 2008 - 2010 -3
Esophagus 6.5 1.2 12.1 0 2002 - 2004 25.8 2004 - 2008 8.1 2008 - 2010 -12.6
Stomach 10.0 8.8 17.5 0 2002 - 2004 34.8c 2004 - 2008 6 2008 - 2010 -3.3
Colorectal 15.2 12.4 18.0 0 2002 - 2004 39.2 2004 - 2008 14.2 2008 - 2010 -2.9
Bladder 9.6 5.4 13.9 0 2002 - 2004 35.4 2004 - 2008 8.1 2008 - 2010 -8.9
Prostate 17.4 12.1 22.9 0 2002 - 2004 41.9 2004 - 2008 13.4 2008 - 2010 3.9
Female
All sites 11.6 11.4 11.8 0 2002 - 2004 27.3c 2004 - 2008 10.9c 2008 - 2010 -0.8
Esophagus 5.9 4.9 6.9 0 2002 - 2004 27.4c 2004 - 2008 5.8 2008 - 2010 -11.9
Stomach 10.0 3.9 16.6 0 2002 - 2004 25.4 2004 - 2008 8.7 2008 - 2010 -1.1
Colorectal 14.4 13.4 15.5 0 2002 - 2004 37.1c 2004 - 2008 12.0c 2008 - 2010 -0.3
Breast 10.9 4.9 17.2 0 2002 - 2005 21 2005 - 2008 11.4 2008 - 2010 -3.4
Thyroid 12.9 3.0 23.7 0 2002 - 2005 26.7 2005 - 2008 6.3 2008 - 2010 3.9
a Average annual percent change.
b Annual percent change.
c APC is significantly different from 0 (P < 0.05).
Table 2. Trends in Age-Standardized Mortality Rates for All and Major Cancers in Iran Among Men and Women According to the Joinpoint Analysis in 2006 - 2011
AAPC in 2006 - 2011 Trend 1 Trend 2
AAPC 95% Confidence Interval P Value Years APCa Years APC
Lower Upper
Males
All sites 0.4 -5.8 7.0 0.9 2006 - 2009 -0.6 2009 - 2011 1.9
Esophagus -4.9 -6.6 -3.2 0.0 2006 - 2008 -6.7 2008 - 2011 -3.8
Stomach -5.5 -11.3 0.6 0.1 2006 - 2009 -2.0 2009 - 2011 -10.5
Colorectal 4.6 3.3 5.8 0.0 2006 - 2008 14.4 2008- 2011 -1.6
Bladder -3.8 -4.5 -3.2 0.0 2006 - 2009 -3.6 2009 - 2011 -4.2
Prostate 1.6 -11.9 17.1 0.8 2006 - 2009 -2.0 2009 - 2011 -10.5
Female
All sites 0.1 -7.7 8.6 1.0 2006 - 2009 -2.0 2009 - 2011 3.4
Esophagus -5.4 -8.3 -2.5 0.0 2006 - 2008 -2.3 2008 - 2011 -7.4
Stomach -5.4 -13.3 3.3 0.2 2006 - 2009 -5.1* 2009 - 2011 -5.9
Colorectal -1.2 -1.2 -1.2 0.0 2006 - 2008 0.7* 2008 - 2011 -2.5*
Breast 3.7 -5.5 13.8 0.4 2006 - 2009 1.0 2009 - 2011 7.8
Thyroid -1.2 -6.7 4.5 0.7 2006 - 2008 2.2 2008 - 2011 -3.5
aAPC is significantly different from 0 (P < 0.05).
are low in Europe and Northern America (7). In the present
study, the trend for stomach cancer showed an increasing
of incidence, while mortality decreased form 2006-2011.
A previous study reported an increasing trend for the
incidence of stomach cancer in both males and females
(20). Explanations for the increase in incidence include
higher exposure to Helicobacter pylori (21), unhealthy di-
ets, consumption of salty foods, and lower rates of con-
sumption of fruits and fresh vegetables (22). Despite the
gradual decline in the global mortality rates, stomach can-
cer was a major cause of death in the present study for
both males and females. Overall, age-standardized mor-
tality rates in both developing and developed countries
(23) show a steady decrease which could be attributed to
healthier diets (24).
In the present study, the results showed that bladder
cancer was the third most common cancer in males, but
not among the top five most prevalent cancers in females.
A previous study noted a slight decline (from 1.12 to 1.09 per
100,000) in Iran from 2006 to 2010 (25). Numerous stud-
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Table 3. Crude and Age-Standardized Mortality Rates for Major Cancers in Iran Among Men and Women in 2006 - 2011
Male Female
2006 2011 2006 2011
CDR ASMR CDR ASMR CDR ASMR CDR ASMR
All sites 56.4 70.5 65.4 75.0 35.1 45.4 43.6 48.8
Esophagus 3.3 4.3 2.8 3.3 2.3 3.0 2.0 2.4
Stomach 13.1 16.7 11.3 12.5 6.7 9.0 6.1 6.9
Colorectal 2.0 2.5 2.8 3.2 1.6 2.2 2.0 2.2
Bladder 1.6 2.0 1.4 1.7 - - - -
Prostate 4.6 5.5 6.1 6.3 - - - -
Thyroid - - - - 0.2 0.30 0.3 0.31
Breast - - - - 3.5 4.5 5.1 5.7
Abbreviations: CDR, crude death rate; ASMR, age-standardized mortality rate per 100,000.
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Figure 1. Observed and Modeled Age-Standardized Incidence Rates Per 100,000 Population (Males; Solid Line, Females; Dashed Line) and the ‘Best’ Joinpoint Model Estimates
for the Selected Cancer Sites by Gender
ies have listed tobacco as a leading risk factor for bladder
cancer (26, 27). Some studies have shown a decline in both
bladder cancer mortality and incidence with reducing to-
bacco use rates (28, 29); however, there is no evidence for
changes in the trend of tobacco use in Iran (30).
Globally, the incidence of thyroid cancer has increased
and the mortality rate has decreased in recent decades (31,
32). Apparently, in Iran, the increase in the number of ra-
diologists and other skilled medical specialists is the rea-
son for the rise in the incidence rates (33), while social de-
terminants have affected the mortality rate, as well (34).
In females, breast cancer was the most common and the
main cause of death from cancer globally (1). In the present
study, the incidence rate increased up to 2008 and de-
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Figure 3. Trends in age-Standardized Incidence Rates (Per 100,000 Population) of
Common Cancers in Females in 2002 - 2010
creased slightly afterwards. Nevertheless, another study
noticed a decreasing trend in the incidence of breast can-
cer (35).
The increased risk of developing cancer is related to fe-
male reproductive history, such as sex-related endogenous
hormones, advanced age at first live birth, and lifestyle
factors such as a westernized diet and anthropometric in-
dices, including body mass index (35). The decrease in the
global incidence could be attributed to improved screen-
ing programs and mammography, as well as the decrease
in hormone therapy in some countries (3, 36).
In the present study, both the incidence and mortality
of prostate cancer showed increasing trends which were
not significant; changes in lifestyle and aging of the popu-
lation could be also held accountable (37). Despite the rise,
the incidence rate of prostate cancer in Iran is lower than
some developed countries, which can partly be explained
by the lack of national screening programs in Iran (38).
The increasing trend in the incidence of colorectal can-
cer in the present study, as shown by two systematic re-
views in Iran, has been reported for both genders (39,
40). The main reasons are lifestyle changes (to a western
lifestyle) and increased consumption of fast foods (41). The
incidence of colorectal cancer increased in conjunction
with improvements in the detection of (glandular) polyps,
which have been shown to be effective in developed coun-
tries (42). Overall, there is a need to implement screen-
ing and treatment programs in Iran. In a previous study,
the mortality rate of colorectal cancer showed a decreasing
trend (43). Early detection and cancer registry are proba-
ble reasons for the declining trend in mortality; however,
one should not forget the variation in cancer incidence, ob-
tained from cancer registries.
This study presented a comprehensive image of com-
mon cancer trends in Iran for one decade. The data analy-
sis was based on the most developed method of time-trend
analysis in the world. The results can help future studies on
the accuracy of cancer registry in Iran, although complete-
ness of the cancer registry in some parts of the country is
questionable.
5.1. Limitations
The mortality data was unavailable for the period be-
fore 2006; as a result, proper comparisons could not be
made between the nine-year incidence and mortality rates.
Another shortcoming of the present study was the time pe-
riod of the study. It should be noted that the overall change
in the incidence and mortality rates of cancer is a long pro-
cess.
5.2. Conclusion
Despite limitations, the results of this study could pro-
vide comprehensive information on the patterns of the in-
cidence and mortality of cancer in Iran and could be useful
for policymakers and health administrators in the devel-
opment of more precise cancer control programs. Many
factors are known responsible for the increasing trends
in cancer incidence rates. In Iran, these include rapid
changes in lifestyle and increasing exposure to risk factors.
However, improved registry systems and declining mortal-
ity rates can result in early detection and treatment.
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Figure 4. Observed and Modeled Age-Standardized Mortality Rates Per 100,000 Population (Males; Solid Line, Females; Dashed Line) and the ‘Best’ Joinpoint Model for the
Selected Cancer Sites by Gender
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